This summary was created by AI, based on 1 opinions in the last 12 months.
According to experts, the performance of Novavax Inc (NVAX-Q) since Covid has been disappointing, resulting in significant losses for investors. The company's stock has been struggling, and there are concerns about its ability to recover. The lack of positive developments and the ongoing challenges faced by the company have led to a pessimistic outlook among experts. Overall, the consensus is that Novavax Inc has underperformed and faces significant obstacles in the current market.
It's not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.
NVAX vs. PFE He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others, but a great long-term investment if you think rates will stay lower. PFE is mature, decent balance sheet, good valuation.
Novavax Inc is a American stock, trading under the symbol NVAX-Q on the NASDAQ (NVAX). It is usually referred to as NASDAQ:NVAX or NVAX-Q
In the last year, 1 stock analyst published opinions about NVAX-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novavax Inc.
Novavax Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Novavax Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Novavax Inc In the last year. It is a trending stock that is worth watching.
On 2024-12-06, Novavax Inc (NVAX-Q) stock closed at a price of $9.25.
Since Covid, this has lost too much money for investors.